Y-mAbs Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
202 Carnegie Ctr Ste 301, Princeton, New...Phone Number
(646) 885-8505Website
www.ymabs.comRevenue
$85.4 MillionIndustry
About Y-mAbs Therapeutics
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.Explore more
Y-mAbs Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Y-mAbs Therapeutics
Compare insights from companies similar to Y-mAbs Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Y-mAbs Therapeutics
$85.4M
51-200
Private
$434.2M
2015
TG
Thomas GadFounder & Chair Chief Business Officer
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Y-mAbs Therapeutics Tech Stack
A closer look at the technologies used by Y-mAbs Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Y-mAbs Therapeutics
Sign Up For FreeTo access detailed company insights
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivot... Read More
